CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 42,188 enrolled
Drug / intervention
IV rtPA (intravenous recombinant plasminogen activator)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04290494
NCT04290494N/ACompleted

Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007 2017: Analysis of China National Stroke Registry (CNSR) I, II, and III

Boehringer Ingelheim·observational·Posted Mar 2, 2020·Updated Nov 5, 2021

In Brief

An observational study evaluating IV rtPA (intravenous recombinant plasminogen activator) for Stroke. Completed, enrolled 42,188 participants across 1 site.

Detailed Summary

The present study is to be conducted based on the AIS patient data collected from CNSR I, II, and III. The primary objectives are: * To investigate the temporal changes in the proportion of intravenous recombinant plasminogen activator (IV rtPA) treatment from 2007 to 2017 among Intravenous Thrombolytics (IVT) eligible patients (patient groups B and B') and overall AIS patients (patient group A) in China; * To investigate the temporal changes in IV rtPA treatment time intervals from 2007 to 2017 among IV rtPA treated patients (patient groups C and C') in China. The secondary objectives are: \- To describe the demographic and clinical characteristics of the IV rtPA treated patients (patient groups C and C'), IVT eligible patients (patient groups B and B') and the overall AIS patients (patient group A) from 2007 to 2017 from the CNSR I to III.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsStroke
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedMar 2, 2020
Enrollment StartSep 21, 2020
Primary CompletionSep 30, 2020
TodayJul 2, 2026
Enrollment to primary: 9 daysPosted 6.3 years ago

Interventions

IV rtPA (intravenous recombinant plasminogen activator)drug

intravenous injection